Hirota K, Browne T, Appadu B L, Lambert D G
Department of Anaesthesia, Leicester Royal Infirmary.
Br J Anaesth. 1997 Feb;78(2):185-8. doi: 10.1093/bja/78.2.185.
We have examined the interaction of procaine, prilocaine, lignocaine, bupivacaine, amylocaine and R(+) and S(-) ropivacaine with L-type voltage-sensitive Ca2+ channels in rat cerebrocortical membranes. Membranes were prepared in Tris HCl 50 mmol litre-1, pH 7.4, by homogenization and centrifugation. Binding assays were performed in 1-ml volumes of Tris HCl 50 mmol litre-1, pH 7.4, for 90 min at room temperature using approximately 200 micrograms of protein. Non-specific binding was defined in the presence of nifedipine 10(-5) mol litre-1, and bound and free radioactivity were separated by vacuum filtration. The effects of local anaesthetics were determined by displacement of [3H]PN200-110 (approximately 0.2 nmol litre-1), a radiolabelled 1,4- dihydropyridine (DHP) L-channel antagonist. The concentration of displacer producing 50% displacement was corrected for the competing mass of [3H]PN200-110 to yield the affinity constant, K50. All local anaesthetics displaced [3H]PN200-110 in a dose-dependent manner with a rank order potency of (K50, mmol litre-1) bupivacaine (0.48), amylocaine (0.74), lignocaine (1.09), prilocaine (2.06) and procaine (2.09). Ropivacaine enantiomers did not show stereo-selective displacement, with K50 values of 0.99 and 0.92 mmol litre-1 for R(+) and S(-) ropivacaine, respectively. There was a significant correlation between pK50 and p (octanol:buffer partition coefficient) (r2 = 0.872, P = 0.020), pK50 and p (local anaesthetic potency) (r2 = 0.816, P = 0.036), pK50 and p (relative conduction blocking potency) (r2 = 0.843, P = 0.028) and between pK50 and p (IC50 for inhibition of cardiac output) (r2 = 0.897, P = 0.015). These data suggest that DHP binding sites may be involved in both the mechanism of local anaesthesia and the cardiotoxicity of these agents.
我们研究了普鲁卡因、丙胺卡因、利多卡因、布比卡因、阿替卡因以及R(+)和S(-)罗哌卡因与大鼠大脑皮质膜中L型电压敏感性Ca2+通道的相互作用。通过匀浆和离心,在50 mmol/L Tris HCl(pH 7.4)中制备膜。结合试验在50 mmol/L Tris HCl(pH 7.4)、1 ml体积中于室温下进行90分钟,使用约200微克蛋白质。非特异性结合在10(-5) mol/L硝苯地平存在下定义,结合和游离放射性通过真空过滤分离。局部麻醉药的作用通过[3H]PN200 - 110(约0.2 nmol/L)的置换来确定,[3H]PN200 - 110是一种放射性标记的1,4 - 二氢吡啶(DHP)L通道拮抗剂。产生50%置换的置换剂浓度针对[3H]PN200 - 110的竞争质量进行校正,以得到亲和常数K50。所有局部麻醉药均以剂量依赖性方式置换[3H]PN200 - 110,其效价顺序为(K50,mmol/L)布比卡因(0.48)、阿替卡因(0.74)、利多卡因(1.09)、丙胺卡因(2.06)和普鲁卡因(2.09)。罗哌卡因对映体未表现出立体选择性置换,R(+)和S(-)罗哌卡因的K50值分别为0.99和0.92 mmol/L。pK50与p(辛醇:缓冲液分配系数)(r2 = 0.872,P = 0.020)、pK50与p(局部麻醉药效能)(r2 = 0.816,P = 0.036)、pK50与p(相对传导阻滞效能)(r2 = 0.843,P = 0.028)以及pK50与p(抑制心输出量的IC50)(r2 = 0.897,P = 0.015)之间存在显著相关性。这些数据表明DHP结合位点可能参与局部麻醉机制以及这些药物的心脏毒性。